Adverse effects of class I antiarrhythmic drugs

Drug Safety

Volumn 17, Issue 1, 1997, Pages 8-36

  Caron, Jacques ^a   Libersa, Christian ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIBENZOLINE; CIMETIDINE; DIGOXIN; DISOPYRAMIDE; FLECAINIDE; LIDOCAINE; MORACIZINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PROPAFENONE; QUINIDINE; QUINIDINE DERIVATIVE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TOCAINAMIDE; TRIMETHOPRIM;

DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG MECHANISM; HEART ARRHYTHMIA; HEART CONDUCTION; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHY; PRIORITY JOURNAL; REVIEW; SODIUM CURRENT;

EID: 0030849406     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717010-00002     Document Type: Review

References (366)

1. Vaughan-Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jansen E, Olesen KH, editors. Proceeding of the Symposium on cardiac arrhythmias. Södertälje Astra AB, 1970: 449-72
2. Cardiac Arrhythmia Suppression Trial (CAST). Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12
3. Boissel JP, Collet JP, Lievre M, et al. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993; 22: 356-63
4. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature heals and mortality after myocardial infarction. N Engl J Med 1977; 247: 750-7
5. Moss AJ, Davis HT, De Camilla J, et al. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1979: 60: 998-1003
6. Bigger Jr JT, Fleiss JL, Kleiger R, Multicenter Post-Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250-8
7. Bigger Jr JT, Weld FM, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia (three or more complexes) detected with ambulatory electrocardiographic recording in the late hospital phase of acute myocardial infarction. Am J Cardiol 1981; 48: 815-23
8. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 1983; 52: 32C-6C
9. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331: 785-91
10. Woosley RL. Antiarrhythmic agents: pharmacokinetics and pharmacodynamics. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology. Philadelphia: Saunders, 1990: 872-82
11. Colatsky TJ. The Sicilian Gambit and antiarrhythmic drug development. Cardiovasc Res 1992; 26: 562-5
12. Grant AO, Starmer CF, Strauss HC. Anliarrhythmic drug action: blockade of the inward sodium current. Circ Res 1984; 55: 427-39
13. Sadanaga I, Ogawa S, Okada Y, et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 1993; 126: 114-21
14. Ranger S, Talajic M, Lemery R, et al. Amplification of flecainide-induced ventricular conduction slowing by exercise: a potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 1989; 79: 1000-6
15. Harrison DC, Winkle PA, Sami M, et al. Encainide: a new potent antiarrhythmic agent. Harrison DC, editor. Cardiac arrhythmias: a decade of progress. Boston: GK Hall, 1981: 315-30
16. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-47
17. Vaughan-Williams EM. Subgroups of class I antiarrhythmic drugs. Eur Heart J 1984; 5: 96-8
18. Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983; 17: 344-52
19. Harrison DC. Is there a rational basis for the modified classification of antiarrhythmic drugs. In: Morganroth J, Moore EN, editors. Cardiac arrhythmias: new therapeutic drugs and devices. Boston (MA): Nijhoff, 1985: 36-48
20. Vaughan-Williams EM. Classifying antiarrhythmic actions: by facts or speculation. J Clin Pharmacol 1992; 32: 964-77
21. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse-use dependence. Circulation 1990; 81: 686-90
22. Colatsly TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235-42
23. Podrid J. Safety and toxicity of antiarrhythmic drugs: benefit versus risk. J Cardiovasc Pharmacol 1991; 17 Suppl. 6: 65-73
24. Ravid S, Podrid PJ, Lampen S, et al. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14: 1326-30
25. Campbell NPS, Kelly JG, Chaturvedi NC, et al. The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J 1977; 53 Suppl. 1: 114-9
26. Kostis JB, Davis D, Kluger J, et al. Cifenline in the short-term treatment of patients with ventricular premature complexes: a double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1989; 14: 88-95
27. 2+ exchange in negative inotropic effects of class I antiarrhythmic drugs on rabbit and rat ventricles. J Cardiovasc Pharmacol 1996; 27: 355-61
28. Chapman RA, Coray A, McGuigan JAS. Sodium-calcium exchange in mammalian heart: the maintenance of low intracellular calcium concentration. In: Drake-Holland AJ, Noble MlM, editors. Cardiac metabolism. Chichester: John Wiley & Sons, 1983: 117-49
29. Kihara Y, Inoko M, Hatakeyama N, et al. Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effect of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. J Cardiovasc Pharmacol 1996; 27 (1): 42-51
30. Brogden RN, Todd PA. Disopyramide: a reappraisal of its pharmacody namic and pharmacokinetic properties and therapeutic use in cardiac arrhythmias. Drugs 1987; 34: 151-87
31. Stewart DE, Ikram H. The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. NZ Med J 1984; 97: 148-50
32. Ready CP, Benes J, Beck B. Intravenous disopyramide: safety and efficacy of a new dosage regimen. Clin Pharmacol Ther 1984; 35: 610-6
33. Meffin PJ, Roberts EW, Winkle RA, et al. The role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm 1979; 7: 29-46
34. Greene AC, Iskandrian AS, Hakki AH, et al. Effects of oral disopyramide therapy on left ventricular function. Chest 1983; 83: 480-4
35. Kowey PR, Friedman PL, Podrid PJ, et al. Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. Am Heart J 1982; 104: 769-4
36. Alboni P, Paparella N, Cappato R, et al. Direct and autonomically mediated effects of oral flecainide. Am J Cardiol 1988; 61: 759-63
37. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989; 80: 1571-9
38. Schlepper M. Cardiodepressive effects of antiarrhythmic drug. Eur Heart J 1989; 10 Suppl. E: 73-80
39. Ledda F, Mantelli L, Munzini S, et al. Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 1981; 3: 1162-73
40. Brodsky MA, Allen BJ. Ventricular tachycardia in patients with impaired left ventricular function: the role of propafenone. Clin Prog Electrophysiol Pacing 1986; 4: 546-52
41. Tamargo J, Delgado C. Electrophysiological effects of propafenone on isolated guinea pig ventricular muscle and sheep Purkinje fibers. Eur J Pharmacol 1985; 118: 331-40
42. Millar JS, Vaughan Williams EM. Effects on rabbit nodal, atrial. ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol 1982; 75: 469-78
43. Murakawa Y, Inoue H, Kuo T-T, et al. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation: efficiency during treatment with Class I antiarrhythmic agents. J Cardiovasc Pharmacol 1995; 25: 194-90
44. Tworek DA, Nazari J, Ezri M, et al. Interference of antiarrhythmic agents with function of electrical cardiac devices. Clin Pharm 1992; 11: 48-56
45. Hellestrand K J, Burnett PJ, Milne JR, et al. Effect of the antiarrhythmic agent flecainide on acute and chronic pacing thresholds. Pacing Clin Electrophysiol 1983; 6: 892-9
46. Horowitz LN, Zipes DP, Bigger Jr JT. et al. Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia: a status report. Am J Cardiol 1987; 59 Suppl.: 54E-6E
47. Caron J, Libersa C, Guedon-Moreau L, et al. Des effets antiarythmiques aux effets proarythmiques. Therapie 1992; 47: 359-61
48. Levine JH, Morganroth J, Kadish AH. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Circulation 1989; 80: 1063-9
49. Ikeda N, Singh BN, Davis LO, et al. Effect of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 1985; 5: 303-10
50. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966; 59: 263-72
51. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115-72
52. Antzelevitch C, Jorge M, Davidenko JM. Quinidine-induced early after depolarizations and triggered activity. J Electrophysiol 1989; 3 (5): 323-8
53. Fautrez VM, Adamantidis MM, Caron J, et al. Comparative electrophysiological effects of metabolites of quinidine and hydroquinidine. J Cardiovasc Pharmacol 1992; 19: 308-18
54. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 1985; 56: 857-67
55. Davy JM, Weissenburger J, Chezalviel F, et al. Experimental arrhythmogenicity of quinidine: effects of dose and route of administration. J Electrophysiol 1989; 3 (5): 339-45
56. El Sherif N, Zeiller RH, Craelius W, et al. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations: after depolarizations and ventricular arrhythmias. Circ Res 1988; 63: 286-305
57. Fautrez VM, Adamantidis MM, Guillaume MC, et al. Comparative electrophysiologic effects of hydroquinidine and quinidine in guinea-pig papillary muscle: frequency and voltage dependence. J Electrophysiol 1989; 3: 353-61
58. Surawicz B. Electrophysiologic substrate of torsades de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol 1989; 14: 172-84
59. Roden DM, Woosley RL. QT prolongation and arrhythmia suppression. Am Heart J 1985; 109: 411-5
60. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; III: 1088-93
61. Oberg KC, O'Toole MF, Gallastegui JL, et al. 'Late' proarrhythmia due to quinidine. Am J Cardiol 1994; 74: 192-4
62. Kimura Y, Takayanagi K, Sakai Y, et al. Torsades de pointes in paced patients with sick sinus syndrome after disopyramide administration. Jpn Heart J 1994; 35: 153-61
63. Krikler DM, Curry PVL. Torsades de pointes, an atypical ventricular tachycardia. Br Heart J 1976; 38: 117-20
64. Cocco G, Strozzi C, Ghu D, et al. Torsades de pointes as a manifestation of mexiletine toxicity. Am Heart J 1980; 100: 878-0
65. Crijns HJ, Kingma JH, Viersma JW, et al. Transient giant inverted T waves during flecainide intoxication. Am Heart J 1987; 113: 214-5
66. Said SAM, Somera ST, Oude Luttikhuis HA. Flecainide-induced QT prolongation, T wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation. Int J Cardiol 1994; 44: 285-7
67. Wickers F, Haissaguère M, Palussière J. Allongement de QT et induction de torsades de pointe par le flécaïnide: a propos d'un cas. Arch Mal Coeur 1988; 81: 1283-5
68. Roden DM. The long QT syndrome and torsades de pointes: basic and clinical aspects. In: El-Sherif N, Samet P. editors. Cardiac pacing and electrophysiology. 3rd ed. Philadelphia: W.B. Saunders, 1991: 265-84
69. Damiano BP, Rosen M. Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation 1984; 69: 1013-25
70. Botting JH, Curtis MJ, Walker MJ. Arrhythmias associated with myocardial ischemia and infarction. Mol Aspects Med 1985; 8: 307-422
71. Roberts R, Ambos HD, Loof CW, et al. Initiation of repetitive ventricular depolarization by relatively late premature complexes in patients with acute myocardial infarction. Am J Cardiol 1978; 41: 678-83
72. Tye KH, Samant A, Desser KB, et al. R on T or R on P phenomenon? Relation to the genesis of ventricular tachycardia. Am J Cardiol 1979; 44: 632-7
73. Gillis AM, Kates RE. Influence of protein binding on the cardiac uptake and pharmacodynamics of propafenone. Cardiovasc Research 1988; 12: 526-34
74. Aupetit JF, Timour Q, Loufoua-Moundanga J, et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995; 25 (5): 810-6
75. Pacini DJ, Boachie-Ansah G, Kane KA. Modification by hypoxia, hyperkalaemia and acidosis of the cardiac electrophysiological effects of a range of antiarrhythmic drugs. Br J Pharmacol 1992; 107: 665-70
76. Nelson SD, Coyne KS, Meimer J. The discordant influences of infarct healing on the electrophysiologic effects of procainamide and N-acetylprocainamide. J Pharmacol Exp Ther 1995; 273 (1): 315-9
77. Haverkamp W, Hindricks G, Fechtrup C, et al. Sodium channel blockers in the treatment of ventricular arrhythmias: different effects in the normal, ischaemic or failing heart? Eur Heart J 1991; 12 Suppl. F: 10-7
78. Fagbemi SO, Chi L, Lucchesi BR. Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents. J Cardiovasc Pharmacol 1993; 21: 709-19
79. Akhtar M, Breithardt G, Camm AJ, Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. CAST and beyond: implications of the cardiac arrhythmia suppression trial. Circulation 1990; 81 (3): 1123-7
80. Timour Q, Aupetit JF, Loufoua-Moundanga J, et al. Role of asynchronous activation of the ventricular fibres by an ectopic pacemaker in the accidents, especially fibrillation, caused by Ic antiarrhythmic drugs. Fundam Clin Pharmacol 1992; 6: 159-67
81. Pogwizd SM, Corr PB. Biochemical and electrophysiological alterations underlying ventricular arrhythmias in the failing heart. Eur Heart J 1994; 15 Suppl. D: 145-54
82. Beuckelmann DJ, Nabauer M, Ardmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85: 1046-55
83. Aronson RS, Mina Z. Cellular mechanisms of arrhythmias in hypertrophied and failing myocardium. Circulation 1993; 87 Suppl. VII: 76-83
84. Gamier D. Attachment procedure of mechanism manipulation of isolated cardiac myocytes: a challenge to cardiovascular research. Cardiovasc Res 1994; 28: 1558-64
85. Kottkcamp M, Budde B, Lamp W, et al. Clinical significance and management of ventricular arrhythmias in heart failure. Eur Heart J 1994; 15 Suppl. D: 155-63
86. Zipes DP. Proarrhythmic effects of antiarrhythmic drugs. Am J Cardiol 1987; 59: 26E-31E
87. Bigger Jr JT, Sahar DI. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol 1987; 59: 2E-9E
88. Akiyama T, Pawitan Y, Campbell WB, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. J Am Geriatr Soc 1992; 40: 666-72
89. Nestico PF, Morganroth J. Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. Cardiol Clin 1986; 4: 285-303
90. Hayakawa H, Ino T. Antiarrhythmic therapy in the elderly. Jpn J Geriatr 1994; 31: 1192-7
91. Pfeifer HJ, Greenblatt DJ, Koch Wiser J. Clinical use and toxicity of intravenous lidocaine. Am Heart J 1976; 92: 168-73
92. Podrid PJ, Levine PA, Klein MP. Effect of age on antiarrhythmic drug efficacy and toxicity. Am J Cardiol 1989; 63: 735-9
93. kr: implications for torsades de pointes and reverse use-dependence. Circulation 1996; 93: 407-11
94. Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118: 433-40
95. Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs: incidence and predictors. Am J Cardiol 1987; 59 Suppl.: 38E-44E
96. Winkle RA, Mason JW, Griffin JC. Malignant ventricular tachycardia associated with the use of encainide. Am Heart J 1981; 102: 857-64
97. Benditt DG. Proarrhythmia: recognition of patients at risk. J Cardiovasc Electrophysiol 1991 Suppl.: S221-32
98. Slater W, Lampert S, Podrid PJ, et al. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 1988; 61: 349-53
99. Soyka LF. Safety of encainide for the treatment of ventricular arrhythmias. Am J Card 1986; 58: 96C-103C
100. Soyka L, Overfield S, Verjee S. Risk factors for death and proarrhythmia in antiarrhythmia drug trials [abstract]. Acta Pharmacol Toxicol 1986; 59 Suppl. 5: 41
101. Josephson R, Papa L, Brooks M, CAST Investigators. Effect of age on postmyocardial infarction ventricular arrhythmias (Holter registry data from CAST I and CAST II). Am J Cardiol 1995; 76: 710-3
102. Duff HJ, Roden D, Primm RK et al. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 1983; 67: 1124-28
103. Rae AP, Kay HR, Horowitz LN, et al. Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. J Am Coll Cardiol 1988; 12: 131-9
104. Libersa C, Caron J, Guedon-Moreau L, et al. Adverse cardiovascular effects of antiarrhythmic drugs. Part I: proarrhythmic effects. Therapie 1992; 47: 193-8
105. Morganroth J, Horowitz L. Flecainide: its pro-arrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984; 53: 89B-94B
106. Velebit U, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65: 886-94
107. Anastasiou-Nana MI, Menlove RL, Nanas JN, et al. Changes in spontaneous variability of ventricular ectopic activity as a function of time in patients with chronic arrhythmias. Circulation 1988; 78: 286-95
108. Pratt CM, Slymen DJ, Wierman AM, et al. The changing baseline of complex ventricular arrhythmias: a new consideration in assessing long-term antiarrhythmic drug therapy. N Engl J Med 1985; 313: 1444-9
109. Schmidt G, Ulm K, Barthel P, et al. Spontaneous variability of simple and complex ventricular premature contractions during long time intervals in patients with severe organic heart disease. Circulation 1988; 78: 296-301
110. Wyse DG, Morganroth J, Lendingham R, et al. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. J Am Coll Cardiol 1994; 23: 1130-40
111. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990; 82: 1106-6
112. Libersa C, Caron J, Guedon-Moreau L, et al. Effets proarythmiques des antiarythmiques: méthodes d'étude et difficultés d'analyse. Therapie 1992; 47: 363-5
113. Boden WE. Meta-analysis in clinical trials reporting: has a tool become a weapon? Am J Cardiol 1992; 69: 681-6
114. Crijns HJ, Van Gelder IS, Be KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988; 62: 1303-6
115. Warringlon SJ, Hamer J. Some cardiovascular problems with disopyramide. Postgrad Med J 1980; 56: 229-33
116. Podrid PJ. Aggravation of arrhythmia: acomplication of antiarrhythmic drugs. J Cardiovasc Electrophysiol 1993; 4: 311-9
117. Ravid S, Podrid PJ, Novrit B. Safety of long-term propafenone therapy for cardiac arrhythmia: experience with 774 patients. J Electrophysiol 1987; 1: 580-90
118. Poole JE, Werner JA, Bardy GH, et al. Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias. Am Heart J 1986; 112: 322-6
119. Adler JB, Goldberg RI. Mexiletine-induced pill esophagitis. Am J Gastroenterology 1990; 85: 629-30
120. Bigger Jr JT, Heissenbuttel RH. The use of procaine amide and lidocaine in the treatment of cardiac arrhythmias. Prog Cardiovasc Dis 1969; 11: 515-34
121. Peterson AM, Conrad SD, Bell JM. Procainamide-induced pseudo-obstruction in a diabetic patient. Drug Intell Clin Pharm 1991; 25: 1334-5
122. Connolly SJ, Kates RE, Lebsack CS. et al. Clinical pharmacology of propafenone. Circulation 1983; 68: 589-96
123. Furlanello F, Disertori M, Veragara G, et al. Clinical evaluation of new antiarrhythmic agents: experiences with propafenone. Int J Clin Pharmacol Res 1983; 3: 101-5
124. Rosketh R, Storstein O. Quinidine therapy of chronic auricular fibrillation. Arch Intern Med 1963; 111: 184
125. Zahger D, Gilon D, Gotsman MS. Delayed quinidine-induced diarrhoea after five years of treatment [letter]. Chest 1992; 101: 296
126. Klein RC, Horwitz LD, Rushforth N. Efficacy and safety of oral cibenzoline for ventricular arrhythmias. Am J Cardiol 1986; 57: 592-7
127. Coumel P, Le Clercq J-F, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 1984; 54: 60D-6D
128. Zipes DP, Troup PJ. New anti-arrhythmic agents: amiodarone. aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil. Am J Cardiol 1978; 41: 1005-24
129. Horn HR, Hadidian Z, Johnson JL, et al. Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J 1980; 100: 1037-40
130. Jeandel C, Bannwarth B, Trechot P, et al. Myoclonic encephalopathy associated with propafenone. Therapie 1990; 45: 161-2
131. Chua TP, Farrell T, Lipkin DP. Myoclonus associated with propafenone [letter]. BMJ 1994; 308: 113-8
132. Lecky BRF, Weir D, Chong E. Exacerbation of myasthenia by propafenone [letter]. J Neurol Neurosurg Psychiatry 1991; 54: 377
133. Miller CD, Oleshansky MA, Gibson KF, et al. Procainamide-induced myasthenia-like weakness and dysphagia [letter]. Ther Drug Monit 1993; 15: 251-4
134. Sayler DJ, Dejong DJ. Possible procainamide-induced myopathy [letter]. Drug Intell Clin Pharmacy 1991; 25: 436
135. Chew CYC, Collett J, Singh BN. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 1979; 17: 161-81
136. Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol 1984; 53 Suppl: 101B-5B
137. Cocco G, Strozzi C, Pansini R, et al. Antiarrhythmic use of cibenzoline, a new class I antiarrhythmic agent with class 3 and 4 properties, in patients with recurrent ventricular tachycardia. Eur Heart J 1984; 5: 108-14
138. Palace J, Shah R, Clough C. Flecainide-induced peripheral neuropathy [letter]. BMJ 1992; 305: 810
139. Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord 1992; 7: 62-3
140. Schwartz AB, Klausner SC, Yee S. et al. Cerebellar ataxia due to procainamide toxicity. Arch Intern Med 1984; 144: 2260-1
141. Currie P, Ramsdale DR. Paranoid psychosis induced by tocainide. BMJ 1984; 288: 606-7
142. Clarke CWF, El-Mahdi EO. Confusion and paranoia associated with oral tocainide. Postgrad Med J 1985; 61: 79-81
143. Ziegelbaum M, Lever H. Acute urinary retention associated with flecainide. Cleveland Clin J Med 1990; 57: 86-7
144. Miura DS, Keren G, Torres V, et al. Antiarrhythmic effects of cibenzoline. Am Heart J 1985; 109: 827-33
145. Browne KF, Prystowsky EN, Zipes DP, et al. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias. J Am Coll Cardiol 1984; 3: 857-64
146. Teichman SL, Fisher JD, Matos JA, et al. Disopyramide-pyridostigmine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 1985; 7: 108-13
147. Prendergast MD, Nasca TJ. Anticholinergic syndrome with procainamide toxicity [letter]. JAMA 1984; 251: 2926-7
148. Morganroth J. Safety and efficacy of a twice-daily dosing regimen for moricizine (ethmozine). Am Heart J 1985; 110: 1188-92
149. Ilett KF, Tjokroseto RR, Benzie JL. Correlation of disopyramide and N-desalkyl disopyramide plasma levels with anticholinergic side effects. Aust J Hosp Pharm 1983; 13: 142
150. Josephson ME, Seides SF, Batsford WP, et al. The electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man. Am Heart J 1974; 87: 55-64
151. Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990; 66: 378-83
152. Marcus FI. The hazard of using type 1 C antiarrhythmic drugs in the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990; 66: 366-7
153. Bender F. Benefit-risk ratio in the treatment of tachyarrhythmias: a clinical judgement. Drugs 1985; 29 Suppl. 4: 65-7
154. Podrid PJ, Morganroth J. Aggravation of arrhythmia during drug therapy: experience with flecainide acetate. Pract Cardiol 1985; 11: 55-70
155. Nelson LD, Schmid PG, Holmsten D, et al. Effects of quinidine on venous responses to adrenergic and nonadrenergic constrictor stimuli: indirect evidence of two sites of action in vascular smooth muscle. Proc Soc Exp Biol Med 1974; 146: 409-13
156. Lee IT, Kroemer HK, Silberstein DI, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990; 322: 1764-8
157. Veale D, McComb JM, Gibson GJ. Propafenone [letter]. Lancet 1990; 335: 979
158. + currents in Xenopus oocytes. Br J Pharmacol 1993; 109: 866-72
159. Cacoub P, Deray G, Baumelou A, et al. Disopyramide-induced hypoglycemia: case report and review of the literature. Fund Clin Pharmacol 1989; 3: 527-35
160. Lefort G, Haissaguerre M, Flora J, et al. Hypoglycémies au cours de surdosages par un nouvel antiarythmique: la cibenzoline; trois observations. Presse Méd 1988; 17: 687-91
161. Houdent C, Noblet C, Vandoren C, et al. Cibenzoline-induced hypoglycemia in the elderly. Rev Med Int 1991; 12: 143-5
162. Montagnac R, Schillinger F. Cibenzoline-induced hypoglycemia in renal failure patients. Sem Hopitaux 1995; 71: 345-7
163. Gross A, Guerci B, Grulet H, et al. Hypoglycaemia induced by cibenzoline [letter]. Diabete Metab 1990; 16: 44
164. + channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline. Br J Pharmacol 1996; 111: 1749-55
165. + channels. Br J Pharmacol 1995; 115: 381-2
166. Aviado DM, Salem H. Drug action and interaction 1. Quinidine for cardiac arrhythmias. J Clin Pharmacol 1975; 15: 477-85
167. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26
168. Daoud EG, Niebauer MJ, Man KC, et al. Prospective assessment of quinidine induced QT prolongation and proarrhythmia in hospitalised patients [abstract]. J Am Coll Cardiol 1995 (special issue): 220
169. Amlie JP, Storstein L, Olsson B, et al. Absolute bioavailability of quinidine in two sustained release preparations. Eur J Clin Pharmacol 1979; 16: 45-8
170. Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients. Prog Cardiovasc Dis 1977; 20: 151-63
171. Shaftel N, Halpern A. The quinidine problem. Angiology 1958; 9: 34-46
172. Almeyda J, Levantine A. Cutaneous reactions to cardiovascular drugs. Br J Dermatol 1973; 88: 313-9
173. Taylor DR, Potashnick R. Quinidine-induced exfoliative dermatitis, with brief review of quinidine idiosyncrasies. JAMA 1951; 145: 641-2
174. Gouffault J, Pawlotsky Y, Morel H, et al. Erythrodermie d'origine quinidinique. Sem Hôp Paris 1965; 41: 1350-3
175. Pariser DM, Taylor JR. Quinidine photosensitivity. Arch Dermatol 1975; 111: 1440-3
176. Lang PG. Quinidine-induced photodermatitis confirmed by photopatch testing. J Am Acad Dermatol 1983; 9: 124-8
177. Bruce S, Wolf JE. Quinidine-induced photosensitive livedo reticularis-like eruption. J Am Acad Dermatol 1985; 12: 332-6
178. Mahler R, Sissons W, Watters K. Pigmentation induced by quinidine therapy. Arch Dermatol 1986; 122: 1062-4
179. Lou CP, Wong KL, Leung WH. Acute lymphadenopathie complicating quinidine therapy. Postgrad Med J 1990; 66: 406-7
180. Bolton FG. Thrombocytopenic purpura due to quinidine: serologic mechanisms. Blood 1956; 2: 547-64
181. Shulman NR. Immunologic reactions to drugs. N Engl J Med 1972; 287: 408-9
182. Lerner W, Caruso R, Faig D, et al. Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood 1985; 66: 306-11
183. Stricker RB, Shuman MA. Quinidine purpura: evidence that glycoprotein V is a target platelet antigen. Blood 1986; 67: 1377-81
184. Ray JB, Brereton WF, Nullet FR. Intravenous immune globulin tor the treatment of presumed quinidine-induced thrombocytopenia. Drug Intell Clin Pharm 1990; 24: 693-5
185. Kaufman DW, Kelly JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82: 2714-8
186. Nieminen U, Kekomaki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug independent platelet antibodies. Br J Haematol 1992; 80: 77-82
187. Sureda A, Hernandez Madrid A, Pérez Vaquera, et al. Quinidine-induced agranulocytosis of abrupt onset. Acta Haematologica 1990; 84 (I): 43-4
188. Barzel US. Quinidine sulfate induced hypoplastic anemia and agranulocytosis. JAMA 1967; 201: 325-7
189. Castro O, Nash I. Quinidine leukopenia and thrombocytopenia with a drug-dependent leukoagglutinin [letter]. N Engl J Med 1977; 296: 572
190. Eisner EV, Carr RM, MacKinney AR. Quinidine-induced agranulocytosis. JAMA 1977; 238: 884-6
191. Geltner D, Chajek T, Rubinger D, et al. Quinidine hypersensitivity and liver involvement. Gastroenterology 1976; 70: 650-2
192. Guharoy SR, Shahin J, Levin S. Quinidine-induced hepatotoxicity revisited. Vet Hum Toxicol 1991; 33: 613-4
193. Bramlet DA, Posalaky Z, Olson R. Granulomatotis hepatitis as manifestation of quinidine hypersensitivity. Arch Intern Med 1980; 140: 395-7
194. Knobler H, Levij IS, Gavish D, et al. Quinidine-induced hepatitis: a common and reversible hypersensitivity reaction. Arch Intern Med 1986; 146: 526-8
195. West SG, McMahon M, Portanova JP. Quinidine-induced lupus erythematosus. Am Intern Med 1984: 100: 840-2
196. Amadio P, Cummings DM, Dashow L. Procainamide, quinidine, and lupus erythematosus [letter]. Ann Intern Med 1985; 102: 419
197. Lavie CJ, Biundo J, Quinet RJ, et al. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med 1985; 145: 446-8
198. McCormack GD, Barth WF. Quinidine induced lupus syndrome. Proc Semin Arthritis Rheum 1985; 15: 73-9
199. Cohen MG, Kevat S, Prowse MV, et al. Two distinct quinidine-induced rheumatic syndromes. Am Intern Med 1988; 108: 369-71
200. Zaidman GW. Quinidine Keratopathic. Am J Ophthalmol 1984; 97: 247-9
201. Hustead JD. Granulomatous uveitus and quinidine hypersensitivity. Am J Ophthalmol 1991; 112: 461-2
202. Poukkula A, Pääkoe P. Quinidine-induced reversible pneumonitis. Chest 1994; 106: 304-6
203. McCord GS, Clouse RE. Pill induced oesophageal strictures: clinical features and risk factors for development. Am J Med 1990; 88: 512-8
204. Bohane TD, Perrault J, Fowler RS. Oesophagitis and oesophageal obstruction from quinidine tablets in association with left atrial enlargement: a case report. Aust Paediatr J 1978; 4: 191-2
205. Giacomini KM, Cox BM, Blaschke TF. Comparative anticholinergic potencies of R- and S-disopyramide in longitudinal muscle strips from guinea pig ileum. Life Sci 1980; 27: 1191-7
206. Doody PT. Disopyramide hepatotoxicity and disseminated intravascular coagulation. South Med J 1982; 75: 496-8
207. Meinertz T, Langer KH, Kasper W, et al. Disopyramide-induced intrahepatic cholestasis [letter]. Lancet 1977; 2: 828
208. Riccioni N, Bozzi L, Susini N. Disopyramide-induced intrahepatic cholestasis [letter]. Lancet 1977; 2: 1362
209. Craxi A, Gatto G, Maringhini A, et al. Disopyramide and cholestasis. Ann Intern Med 1980; 93: 150-1
210. Edmonds ME, Hayler AM. A case of intra-hepatic cholestasis after disopyramide therapy [letter]. Eur J Clin Pharmacol 1980; 18: 285-6
211. Bakris GL, Cross PD, Hammarsten JE, Disopyramide-associated liver dysfunction. Mayo Clin Proc 1983; 58: 265-7
212. Conrad ME, Cumbie WG, Thrasher DR, et al. Agranulocytosis associated with disopyramide therapy [letter]. JAMA 1978; 240: 1857-8
213. Porterfield JG, Amman EM, Lown B. Respiratory difficulty after use of disopyramide [letter]. N Engl J Med 1980; 303: 584
214. Handa SP. Disopyramide-induced toxic cutaneous blisters and coagulopathy. Dialysis Transplant. 1982; 11: 706-7
215. Falk RH, Nisbet PA, Gray TJ. Mental distress in patient on disopyramide [letter]. Lancet 1977; 1: 858-9
216. Padfield PL, Smith DA, Fitzsimons EJ, et al. Disopyramide and acute psychosis [letter]. Lancet 1977; 1: 1152
217. Dawkins KD, Gibson J. Peripheral neuropathy with disopyramide [letter]. Lancet. 1978; 1: 329
218. Tadmor OP, Keren A, Rosenak D, et al. The effect of disopyramide on uterine contractions during pregnancy. Am J Obstet Gynecol 1990; 162: 482-6
219. Stargel WW, Shand DG, Routledge PA, et al. Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading. Am Heart J 1981; 102: 872-6
220. Bromage PR, Robson JD. Concentrations of lignocaine in blood after intravenous, intramuscular, epidural and endotracheal administration. Anesthesia 1961; 16: 461-78
221. Douglas JH, Ross JD, Bruce DL. Delayed awakening due to lidocaine overdose. J Clin Anesthesia 1990; 2: 126-8
222. Palmisano IM, Meliones JN, Crowley DC, et al. Lidocaine toxicity after subcutaneous infiltration in children undergoing cardiac catheterization. Am J Cardiol 1991; 67: 647-8
223. Bauer LA, Brown T, Gibaldi M, et al. Influence of long-term infusion on lidocaine kinetics. Clin Pharmacol Ther 1982; 31: 433-7
224. Halkin H, Meffin, P, Melmon KL, et al. Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite. Clin Pharmacol Ther 1975; 17: 669-76
225. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Int Med 1973; 78: 499-508
226. Tatsukawa H, Okuda J, Kondoh M, et al. Malignant hyperthermia caused by intravenous lidocaine for ventricular arrhythmia. Int Med 1992; 31: 1069-71
227. Manolis AS, Deering TF, Cameron J, et al. Mexiletine: pharmacology and therapeutic use. Clin. Cardiol. 1990; 13: 349-59
228. Leahey EB, Giardina EGV, Bigger Jr JT. Effect of ventricular failure on steady state kinetics of mexiletine [abstract]. Clin. Res 1980; 26: 239
229. Nitsch J, Steinbeck G, Luderitz B. Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease. Eur Heart J 1983; 4: 810-4
230. El Allaf D, Henrard L, Crochelet L, et al. Pharmacokinetics of mexiletine in renal insufficiency. Br J Clin Pharmacol 1982; 14: 431-5
231. Wang T, Wuellner D, Woosley RL, et al. Pharmacokinetics and nondialysability of mexiletine in renal failure. Clin Phamacol Ther 1985; 37: 649-53
232. Yamazaki S, Katayama I, Kurumaji Y, et al. Contact urticaria induced by mexiletine hydrochloride in a patient receiving iontophoresis. Br J Dermatol 1994; 130: 538-40
233. Kikuchi K, Tsunoda T, Tagami H. Generalized drug eruption due to mexiletine hydrochloride: topical provocation on previously involved skin. Contact Dermatitis 1991; 25: 70-2
234. Campbell NPS, Pantridge JF, Adgey AAJ. Long term oral antiarrhythmic therapy with mexiletine. Br Heart J 1978; 40: 796-801
235. Fasola GP, d'Osualdo F, de Pangher V, et al. Thrombocytopenia and mexiletine [letter]. Ann Intern Med 1984; 100: 162
236. Girmann G, Pees H, Scheurlen PG. Pseudothrombocytopenia and mexiletine [letter]. Ann Intern Med 1984; 100: 767
237. Pernot C, Marcon F, Weber JL, et al. Effets indésirables hépatiques de la mexilétine. Thérapie 1983; 38: 695-700
238. Flaker GC, Beach CL, Chapman D. Adverse side effects associated with mexiletine. Clin Prog Electrophysiol Pacing 1986; 4: 602-7
239. Bero CJ, Rihn TL. Possible association of pulmonary fibrosis with mexiletine. Drug Intell Clin Pharm 1991; 25: 1329-33
240. Baker B, Dinh H, Murphy ML. Propafenone: a promising new antiarrhythmic agent. Pract Cardiol 1988; 14: 112-7
241. Somberg JC, Tepper D, Landau S. Propafenone: a new antiarrhythmic agent. Am Heart J 1988; 115: 1274-9
242. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785-91
243. Libersa C, Caron J, Bechtel P, et al. Interest and limitation of phenotype determination of hydroxylation ability in patients treated with propafenone. J Electrophysiol 1987; 1: 466-74
244. Rouet R, Libersa C, Broly F, et al. Comparative electrophysiological effects of propafenone, 5-hydroxypropafenone, and N-depropylpropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol 1989; 14: 577-84
245. Kroemer HK, Fromm MF, Buhl K, et al. An enantiomerenantiomer interaction of (S) and (R) - propafenone modifies the effect of racemic drug therapy. Circulation 1994; 89: 2396-400
246. Kroemer HK, Funck-Brentano C, Silberstein DJ, et al. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 1989; 79: 1068-76
247. Boriani G, Capucci A, Strocchi F, et al. Beta-blocking properties of propafenone in extensive oxidisers: a study on heart rate behaviour during Holter monitoring. Drug Invest 1993; 6: 25-32
248. Gaita F, Richiardi E, Bocchiardo M, et al. Short and long-term effects of propafenone in ventricular arrhythmias. Int J Cardiol 1986; 13: 163-70
249. Guindo J, Rodriguez de la Serna AR, Borja J, et al. Propafenone and a syndrome of the lupus erythematosus type [letter]. Ann Intern Med 1986; 104: 589
250. Hammill SC, Sorenson PB, Wood DL, et al. Propafenone for the treatment of refractory complex ventricular ectopic activity. Mayo Clin Proc 1986; 61: 98-103
251. Spinler SA, Elder CA, Kindwall KE. Propafenone-induced liver injury. Ann Pharmacother 1992; 26: 926-8
252. Mondardini A, Pasquino P, Bernardi P, et al. Propafenone-induced liver injury: report of a case and a review of the literature. Gastroenterology 1993; 104: 1524-6
253. Miwa LJ, Jolson HM. Propafenone-associated agranulocytosis. Pacing Clin Electrophysiol 1992; 15: 387-90
254. Korst HA, Brandes JW, Littmann KP. Potenz- und Spermiogenesestorungen durch Propafenon. Dtsch Med Wochenschr 1980; 105: 1187-9
255. Beckmann J, Hertrampf R, Gundert-Remy U, et al. Is there a genetic factor in flecainide toxicity? [letter] BMJ 1988; 297: 1316
256. Holmes B, Heel RC. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 1-33
257. Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988; 62 Suppl. D: 62-6
258. Birgersdotter LJM, Wong W, Turgeon J, et al. Stereoselective, genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992; 33: 275-80
259. Mikus G, Gross AS, Bekmann J, et al . The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 1989; 45: 562-7
260. Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 1988; 43: 449-55
261. McQuinn RL, Pentikàinen PJ, Chang SF, et al. Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin Pharmacol Ther 1988; 44: 566-72
262. Galloe AM, Graudal N. Cardiac Arrhythmia Suppression Trial. New Engl J Med 1991; 325: 584-5
263. Samlowski WE, Frame RN, Logue GL. Flecainide-induced immune neutropenia: documentation of a hapten-mediated mechanism of cell destruction. Arch Intern Med 1987; 147: 383-4
264. Kuhlkamp V, Haasis R, Seipel L. Flecainidinduzierte Hepatitis. Z Kardiol 1988; 77: 678-80
265. Mikloweit P, Bienmuller H. Medikamentos induzierte intrahepatische Cholestase durch Flecainidacetat und Enalapril. Internist Berl 1987; 28: 193-5
266. Vanderhal AL, Cocjin J, Santulli Jr TV, et al. Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. J Ped 1995; 126: 988-90
267. Mancuso G, Tampieri E, Berdondini RM. Eruzione psoriasiforme da flecainide. G Ital Dermatol Venereol 1988; 123: 171-2
268. Penhall RK, Hong CY, Muhiddin KA. The effect of flecainide on human sperm mobility [abstract]. Br J Clin Pharmacol 1982; 14 Suppl: 147P
269. Zehender M, Treese N, Kasper W et al. Effectiveness and tolerance in long-term treatment with flecainide [bstract]. Circulation 1982; 66 Suppl. II: 144
270. Akoun GM, Cadranel JL, Israel-Biet D, et al. Flecainide-associated pneumonitis [letter]. Lancet 1991; 337: 49
271. Hanston P, Evrard P, Mahieu P, et al. Flecainide-associated interstitial pneumonitis [letter]. Lancet 1991; 337: 371-2
272. Moller HLJ, Thygesen K, Kruit PJ. Corneal deposits associated with flecainide. BMJ 1991; 302: 506-7
273. Canal M, Flouvat B, Tremblay D, et al. Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline. Eur J Clin Pharmacol 1983; 24: 509-15
274. Lee MA, Fenster PE, Garcia ZM, et al. Cibenzoline for symptomatic ventricular arrhythmias: a prospective, randomised, double-blind placebo-controlled trial and a long term open label study. Can J Cardiol 1989; 5: 295-8
275. Opie LH. Aprindine and agranulocytosis [letter]. Lancet 1980; 2: 689-90
276. Zipes DP, Elharrar V, Gilmour RF, et al. Studies with aprindine. Am Heart J 1980; 100: 1055-62
277. Casteels-Van Daele M, Beirinckx J, De Cock, et al. Pancytopenia under treatment with aprindine, a new anti-arrhythmic drug. Acta Paediatr Belg 1977; 30: 247-8
278. Elewaut A, Van Durme JP, Goethals L, et al. Aprindine-induced liver damage. Acta Gastroenterol Belg 1977; 40: 236-43
279. Herlong HF, Reid PR, Boitnott JK, et al. Aprindine hepatitis. Ann Intern Med 1978; 89: 359-61
280. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981; 6: 118-34
281. Habbab MA, El-Sherif N. Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990; 89: 241-6
282. Koch-Weser J. Serum procainamide levels as therapeutic guides. Clin Pharmacokinet 1977; 2: 389-402
283. Woosley RL, Drauer DE, Reidenberg MM, et al. Effect of acetylator phenotype on the rale al which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-9
284. Sim E. Drug-induced immune-complex disease. Complement Inflamm 1989; 6: 119-26
285. Vivino FB, Schumacher HR. Synovial fluid characteristics and the lupus erythematosus cell phenomenon in drug-induced lupus: Undings in three patients and review of pertinent literature. Arthritis Rheum 1989; 32: 560-8
286. Sheikh S, Seggev JS. Procainamide-induced pleural fibrosis. Am J Med 1991; 91: 313-5
287. Weber MT, Hocking WG. Procainamide-induced lupus anticoagulant. Wisc Med J 1988; 87: 30-2
288. Heyman MR, Flores RH, Edelman BB, et al. Procainamide-induced lupus anticoagulant. South Med J 1488; 81: 934-6
289. Smiley JD, Moore SE. Molecular mechanisms of autoimmunity. Am J Med Sci 1988; 295: 478-96
290. Chuang LC, Tunier AP, Akhtar N, et al. Possible case of procainamide-induced intrahepatic cholestatic jaundice. Ann Pharmacother 1993; 27: 434-7
291. Ponte CD, Horner P. Suspected procainamide-induced angioedema [letter]. Drug Intell Clin Pharm 1985; 19: 139-40
292. Prince RA, Brown BT, Jacknowitz A. Agranulocytosis associated with procainamide therapy: report of a case. Am J Hosp Pharm 1977; 34: 1362-5
293. Meisner DJ, Carlson RJ, Gottlieb AJ. Thrombocytopenia following sustained-release procainamide. Arch Intern Med 1985; 145: 700-2
294. Giannone L, Kugler JW, Krantz SB. Pure red cell aplasia associated with administration of sustained-release procainamide. Arch Intern Med 1987; 147: 1179-80
295. Agudelo CA, Wise CM, Lyles MF. Pure red cell aplasia in procainamide-induced systemic lupus erythematosus (report and review of the literature). J Rheumatol 1988; 15: 1431-2
296. Abe H, Stizuka H, Tusaki H, et al. Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction. Jpn Heart J 1995; 36: 483-7
297. Goldsmith AJ, Sehaeffer BT. Necrotizing epiglottitis in a patient with procainamide-induced neutrupenia. Am J Otolaryngol 1994; 15: 58-62
298. Landrum ELM, Siegert EA, Hanlon JT, et al. Prolonged thrombocytopenia associated with procainamide in an elderly patient. Ann Pharmacother 1994; 28: 1172-6
299. Ahn CS, Tow DE. Intrahepatic cholestasis due to hypersensitivity reaction to procainamide. Arch Intern Med 1990; 150: 2589-90
300. Rotmensch HH. Granulomatous hepatitis: hypersensitivity response to procainamide. Ann Intern Med 1978; 89: 646-7
301. Wiegers U, Hanrath N, Kuck KH, et al. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. Eur J Clin Pharmacol 1983; 24: 503-7
302. Braun J, Sorgel F, Engelmaier F, et al. Pharmacokinetics of tocainide in patients with severe renal failure. Eur J Clin Pharmacol 1985; 28: 665-70
303. Farquhar DL, Davidson NM. Possible hepatotoxicity of tocainide. Scott Med J 1984; 29: 238
304. Tucker LE. Tocainide-induced granulomatous hepatitis [letter]. JAMA 1986; 255: 3362
305. Arrowsmith JB, Creamer JL, Bosco L, et al. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med 1987; 107: 693-6
306. Holmes GI, Shapiro DA, Nicolodi LK, et al. Drug therapy: flecainide, and tocainide [letter]. N Engl J Med 1987; 316: 344
307. Volosin K, Greenberg RM, Greenspon AJ. Tocainide associated agranulocytosis. Am Heart J 1985; 109: 1392-3
308. Morrill GB. Tocainide-induced aplastic anemia. Drug Intell Clin Pharm 1989; 23: 90-1
309. Perlow GM, Jam BP, Pauker SG, et al. Tocainide-associated interstitial pneumonitis. Ann Intern Med 1981; 94: 489-90
310. Van Natta B, Lazarus M, Li C. Irreversible interstitial pneumonitis associated with tocainide therapy. West J Med 1988; 149: 91-2
311. Ahmad S. Tocainide: interstitial pneumonitis [letter]. J Am Coll Cardiol 1990; 15: 1458
312. Feinberg L, Travis WD, Ferrans V, et al. Pulmonary fibrosis associated with tocainide: report of a case with literature review. Am Rev Respir Dis 1990; 141: 505-8
313. Miura DS, Wynn J, Laitman R, et al. Ethmozine toxicity: fever of unknown origin. J Clin Pharmacol 1986; 26: 153-5
314. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994; 47: 51-65
315. Martyn R, Somberg JC, Kerin NZ. Proarrhythmia of nonantiarrhythmic drugs. Am Heart J 1993; 126: 201-5
316. Symanski JD, Gettes LS. Drug effects on the electrocardiogram: a review of their clinical importance. Drugs 1993; 46: 219-48
317. Fisch FA, Roden DM. A prolonged QTc interval: is it an important effect of antiarrhythmic drugs? Med Toxicol Adverse Drug Exp 1989; 4: 400-11
318. Monlun E, Pillet O, Cochard JF. Prolonged QT interval with halofantrine [letter]. Lancet 1993; 1541-2
319. Karbwang J, Bangchang KN, Bunnag D, et al. Cardiac effect of halofantrine [letter]. Lancet 1993; 342: 501
320. Singh BN, Gaarder TD, Kanegae T, et al. Liquid proteins diets and torsade de pointes. JAMA 1978; 240: 115-9
321. Zipes DP. Unwitting exposure to risk. Cardiol Rev 1993; 1: 1-3
322. Cumming AD, Robertson C. Interaction between disopyramide and practolol. BMJ 1979; 2: 1264
323. Gelipter D, Hazell M. Interaction between disopyramide and practolol [letter]. BMJ 1980; 280: 52
324. Wyse DG, Kellen J, Tam Y, et al. Increased efficacy and toxicity of lidocaine in patients on betablockers. Int J Cardiol 1988; 21: 59-70
325. Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. Am J Cardiol 1984; 53 Suppl.: 52B-7B
326. Awaji T, Hashimoto K. Antiarrhythmic effects of combined application of class I antiarrhythmic drugs: addition of low-dose mexiletine-enhanced antiarrhythmic effects of disopyramide and aprindine in various-rate canine ventricular tachycardias. J Cardiovasc Pharmacol 1993; 21: 960-6
327. Greenspan AM, Spielman SR, Horowitz N. Combination antiarrhythmic drug therapy for ventricular tachyarrhythmias. Pacing Clin Electrophysiol 1986; 9: 565-76
328. Kim SG, Seiden SW, Matos JA, et al. Combination of procainamide and quinidine for better tolerance and additive effects for ventricular arrhythmias. Am J Cardiol 1985; 56: 84-8
329. Duffy CE, Swiryn S, Bauernfeind RA, et al. Inducible sustained ventricular tachycardia refractory to individual class I drugs: effect of adding a second class I drug. Am Heart J 1983; 106: 450-8
330. Jordaens LJ, Tavernier R, Vanmeerhaeghe X, et al. Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias. Pacing Clin Electrophysiol 1990; 13: 1127-35
331. Schwartz JB, Keefe D, Harrison DC. Adverse effects of antiarrhythmic drugs. Drugs 1981; 21: 23-45
332. Sheldon R, Thakore E, Wilson L. Interaction of drug metabolites with the class I antiarrhythmic drug receptor on rat cardiac myocytes. J Pharmacol Exp Ther 1994; 269: 477-81
333. Hartshorn EA. Interactions of cardiac drugs. Drug Intell Clin Pharm 1970; 4: 272-7
334. Buss J, Lasserre JJ, Heene DL. Asystole and cardiogenic shock due Io combined treatment with verapamil and flecainide [letter]. Lancet 1992; 340: 546
335. Al-Shora HI. Interactions of procainamide, veraparnil, guanethidine and hydralazine with adsorbent antacids and diarrhoeal mixture. Int J Pharmaceutics 1988; 47: 209-13
336. Ragosta M, Weihl AD, Rosenfield LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989; 86: 465-6
337. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet 1997; 349: 326-327
338. Haworth E, Burroughs AK. Disopyramide and warfarin interaction. BMJ 1977; 2: 866-7
339. Sylven C, Anderson P. Evidence that disopyramide does not interact with warfarin. BMJ 1983; 286: 1181
340. Jogestrand T, Schenck-Gustafsson K, Nordlander R, et al. Quinidine-induced changes in serum and skeletal muscle digoxin concentration: evidence of saturable binding of digoxin to skeletal muscle. Eur J Clin Pharmacol 1984; 27: 571
341. Birgersdotter-Green U. Propafenone for cardiac arrhythmias. Am J Med Sci 1992; 303: 123-8
342. Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. N Engl J Med 1976; 294: 699-702
343. Twum-Barima Y, Carruthers SG: Quinidine-rifampin interaction. N Engl J Med 1981; 304: 1466-9
344. Aitio ML, Mansury L, Tala E, et al. The effect of enzyme-induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 1981; 11: 279-85
345. Pentikainen PJ, Koivula IH, Hiltunen HA. Effect of rifampicin treatment on the kinetics of mexiletine. Eur J Clin Pharmacol 1982; 23: 261-6
346. Klein A, Sami M, Selinger K. Mexiletine kinetics in healthy subjects taking cimetidine. Clni Pharmacol Ther 1985; 37: 669-73
347. Pritchett EL, Smith WM, Kirsten EB. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine. J Clin Pharmacol 1988; 28: 619-24
348. Polish LB, Branch RA, Fitzgerald GA. Digitoxin-quinidine interaction: potentiation during administration of cimetidine. South Med J 1981;74: 633-4
349. Ochs HR, Carstens G, Greenblatt DJ. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980; 303: 373-7
350. Tisdale JE, Rudis MI, Padhi ID, et al. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy. J Clin Pharmacol 1996; 36: 3501-6
351. Bax ND, Tucker GT, Lennard MS, et al. The impairment of lignocaine clearance by propranolol: major contribution from enzyme inhibition. Br J Clin Pharmacol 1984; 19: 597-603
352. Scheinman SJ, Poll DS, Wolfson S. Acute cardiac failure and hepatic ischemia induced by disopyramide phosphate. Yale J Biol Med 1980; 53: 361-6
353. Funck-Brentano C, Kroemer HK, Pavlou H, et al. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol 1989; 27: 435-44
354. Broly F, Vandamme N, Libersa C, et al. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol 1991; 32: 459-66
355. Libersa C, Caron J, Broly F, et al. Interaction propafenone mexiletine [letter]. JACC 1993; 22: 2061
356. Mörike K, Magadum S, Mettang T, et al. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. J Intern Med 1995; 238: 469-72
357. Munafo A, Reymond-Michel G, Biollaz J. Altered flecainide disposition in healthy volunteers taking quinine. Eur J Clin Pharmacol 1990; 38: 269-73
358. Holtzman JL, Finley D, Motionen L, et al. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther 1989; 46: 26-32
359. Saal AK, Werner JA, Gross BW, et al. Interaction of amiodarone with quinidine and procainamide [abstract]. Circulation 1982; 66: 224
360. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 1983; 25: 339-5
361. Bauer LA, Black D, Gensler A. Procainamide-cimetidine drug interaction in elderly male patients. J Am Geriatr Soc 1990; 38: 467-9
362. Christian Jr CD, Meredith CG, Speeg Jr KV. Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther 1984; 36: 221-7
363. Kosoglou T, Rocci ML, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin Pharmacol Ther 1988; 44: 467-77
364. Woosley RL. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents with congestive heart failure. Am Heart J 1987; 114: 1280-91
365. Garson Jr A. Dosing the newer antiarrhythmic drugs in children: consideration in pediatric pharmacology. Am J Cardiol 1986; 57: 1405-7
366. Roden DM. The study of pharmacokinetics and pharmacodynamics as a tool for understanding mechanisms of antiarrhythmic drug action. In: Breithardt G, Borggrefe M, Camm J, et al., editors. Antiarrhythmic drugs. Berlin Heidelberg: Springer-Verlag, 1995: 290-9